Published: April 6, 2017; corrected online: May 2, 2017

Introduction {#sec1}
============

Post-transcriptional regulation of gene expression plays a fundamental role in the temporal and spatial modulation of development and has been recently found at the core of many disease mechanisms. In recent years, much progress has been made in unraveling the players in this process, revealing a daunting complexity in the mechanisms of RNA processing and transport. This complexity is not only created by the many players involved and their intricate interactions in multiple aspects of RNA regulation (transcription termination, non-coding RNA interaction, RNA processing, and transport), but is also generated by the complex role of long non-coding RNAs ([@bib15], [@bib49], [@bib55]).

Our zebrafish forward-genetic screen for embryos displaying abnormalities in neural development led to the isolation of a null mutation in the gene encoding splicing factor proline/glutamine-rich (SFPQ, a.k.a. PSF). SFPQ is a multifunctional protein ([@bib66]), known to be involved in pre-mRNA splicing ([@bib63]), transcriptional repression, and DNA repair, originally isolated from the spliceosome. It is associated with nuclear paraspeckles ([@bib20]) involved in nuclear retention of defective RNAs into subnuclear sequestration of SFPQ complexes ([@bib3], [@bib32]) and with small cytoplasmic RNA granules, the function of which is not yet understood ([@bib33]).

The structure of SFPQ is conserved and closely related to NONO and PSPC1 proteins, with which it forms heterodimers. They all contain tandem RNA recognition motif domains, a family-specific NOPS (Nono, Pspc1, and Sfpq) domain and a coiled-coil region ([@bib56]). SFPQ additionally contains a DNA-binding domain (DBD) and an N-terminal proline/glutamine-rich low-complexity region ([@bib43], [@bib57], [@bib58], [@bib66], [@bib79]). Its RNA-binding activity has been implicated in a variety of cellular processes ([@bib9], [@bib18], [@bib45], [@bib63], [@bib67], [@bib66], [@bib73]). Of interest for our study, SFPQ has recently been shown to regulate signal-induced alternative splicing ([@bib61]) and to be required, directly or indirectly, for transport of an RNA regulon that promotes sensory axon viability ([@bib14]). SFPQ is present in cytoplasmic aggregates in brains of patients with a variety of neurodegenerative disorders and is mis-regulated in autism and dyslexia ([@bib10], [@bib35], [@bib39], [@bib71], [@bib74]). The human *SFPQ* gene lies in a region on chromosome 1p34-p36 linked to speech disorders and language impairment ([@bib25], [@bib39], [@bib50], [@bib60], [@bib78]).

Phenotypic characterization of our zebrafish *sfpq* homozygous mutants revealed a restricted set of defects, unexpected for a ubiquitously expressed multifunctional protein. The CNS was prominently affected, showing brain boundary and axonal defects associated with absence of motility. We assessed the specificity of SFPQ functional targets by microarray RNA profiling analysis, comparing the transcriptome of the *sfpq* homozygous mutants to its wild-type and heterozygous siblings at the earliest stage at which the phenotype is robustly recognizable. An unexpectedly narrow set of transcripts was affected by the loss of SFPQ, with a specific enrichment in alternatively spliced neuronal and synaptic transcripts. The use of a tagged version of the protein revealed that SFPQ is abundant in the axons of a subset of neuronal populations including all motor neurons (MNs), an observation confirmed by antibody staining of endogenous SFPQ. We demonstrated that these axons also contain intron-retaining transcripts and spliceosome core components, suggesting a possible involvement in non-canonical cytoplasmic RNA processing. We demonstrate that cytoplasmic SFPQ is functionally relevant to MN differentiation, showing that a non-nuclear version of the protein is able to restore a specific set of neuronal transcripts and rescue the axonal and motility defects in the zebrafish null mutant. The severe motor phenotype of the zebrafish null mutant and presence of SFPQ in aggregates in human degenerative disorders encouraged us to screen ALS patients for *SFPQ* mutations. From these patients, we identified two novel *SFPQ* missense variants affecting the coiled-coil domain of the protein and absent from ∼66,000 normal human exomes. In double-blinded zebrafish null mutant rescue experiments, the ALS-linked SFPQ variants uniquely led to motor axon morphological abnormalities in the rescued mutants and showed a much-reduced cytoplasmic localization. These findings uncover the importance of the non-nuclear axonal function of SFPQ protein in motor development and indicate the importance of the coiled-coil domain in this process.

Results {#sec2}
=======

Loss of Zebrafish sfpq Affects Development of Brain Boundaries and Motor Function {#sec2.1}
---------------------------------------------------------------------------------

A recessive zebrafish mutant identified during a small-scale ENU mutagenesis screen was selected for its early brain boundary defects and was named *coma* due to its vegetative state and its later comma-shaped body ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Preceding any morphologically visible defect, homozygous mutants fail to twitch their tail at 15--16 somite stage (ss). By 24 hr post-fertilization (hpf), all homozygous mutant larvae fail to undergo the morphogenetic changes required to form the posterior mesencephalic wall and a mature isthmic organizer ([Figures 1](#fig1){ref-type="fig"}A and 1B), and 22% have asymmetric ectopic mesencephalic neuroepithelial folds ([Figures 1](#fig1){ref-type="fig"}C and 1D). The expression of midbrain-hindbrain boundary (MHB) markers, *pax2.1* and *fgf8*, is normal at early stages, but reduced or lost at later stages, indicating that the midhindbrain boundary is established, but not maintained ([Figures 1](#fig1){ref-type="fig"}E, 1F, and [S1](#mmc1){ref-type="supplementary-material"}B). The mutant also lacks rhombomere boundaries, failing to express early boundary markers such as *rfng* ([Figures 1](#fig1){ref-type="fig"}G and 1H), and undergoes ectopic neurogenesis in boundary regions ([Figures 1](#fig1){ref-type="fig"}I--1L). These boundary defects are neither due to a general loss of apical-basal polarity, nor to specific cell death in these areas ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2H).Figure 1SFPQ Is Required for Brain BoundariesDorsal (A--D and I--L) and lateral (E--H) views of 32 hpf zebrafish brain with anterior to the top (A and B) or left (C--L).(A and B) Immunostaining of *sfpq; Tg(dlx4.6 GFP)* embryos. Anti-acetylated tubulin staining (red) reveals asymmetrical folds in the midbrain (white arrowheads) and thickening of the isthmic organizer (IsO) in coma mutant (B; n = 8) compared to its wild-type sibling (A; n = 24). GFP staining (green) reveals disorganized neuronal distribution in the cerebellum.(C and D) Dorsal views, anterior to the top, of sibling (C) and mutant (D) *sfpq;Tg(βactin: HRAS gfp)* embryos showing failure of morphological thinning of the isthmus (white arrows in D, n = 9/9) in the homozygous mutant.(E and F) Expression of *pax2.1* in the MHB, greatly reduced in all *sfpq* mutants (F; n = 10) compared to siblings (E; n = 30) at 36 hpf.(G and H) Expression of boundary marker, *rfng*, in siblings (G; n = 21) and mutant (H; n = 7, reduced or absent) at 24 ss.(I and J) Expression of *zash1a* in the hindbrain at 15 ss, in siblings (I; n = 19) and mutant (J; n = 6).(K and L) HuC staining at 32 hpf, in siblings (K; n = 17) and mutant (L; n = 5). Scale bar, 100 μm.(M) Schematic of the *sfpq* gene and the zebrafish and human mutations described in this report and, below, the sequence altered in the zebrafish *coma* mutant.PQ, proline (P) glutamine (Q) rich; RRM, RNA recognition motif; NOPS, NONA/paraspeckle domain; NLS, nuclear localization signals.

Most other aspects of CNS patterning appear normal in the mutant apart from a loss of Wnt signaling activity observed in the hypothalamus ([Figure S1](#mmc1){ref-type="supplementary-material"}D). No significant difference in cell proliferation was found during the two first days of development ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2F and S2I). All mutant embryos develop further defects such as lack of heart looping, pericardial edema, short curved body, and kinky tail ([Figure S1](#mmc1){ref-type="supplementary-material"}A); never acquire motility ([Movie S1](#mmc2){ref-type="supplementary-material"}); and die by 4 days post-fertilization (dpf).

The genetic characterization of *coma*^−/−^ by fine mapping and candidate gene analysis indicated that the genetic lesion was in *sfpq*. This was confirmed by complementation test with an existing allele of the gene (*whitesnake*, *wis*^*tr241*^) ([@bib44]). The point mutation in *coma* was then identified by sequencing as a C-to-T transition at +604 position from the ATG start codon, changing CAA to TAA (glutamine \[Q\] at aa. 203 to STOP codon) in the proline (P)/glutamine (Q)-rich domain of the protein ([Figure 1](#fig1){ref-type="fig"}M). The rescue of the mutant phenotype by microinjection of the zebrafish or human *sfpq* full-length mRNA ([Figures S1](#mmc1){ref-type="supplementary-material"}C and [7](#fig7){ref-type="fig"}) establishes that *coma* is a novel null allele of the gene *sfpq* (named *sfpq*^*kg41*^) located at 56.2 cM on zebrafish chromosome 19 and that the protein has a conserved function in zebrafish and human.

Sfpq Is Cell-Autonomously Required for Motor Axon Development {#sec2.2}
-------------------------------------------------------------

As the earliest observable *sfpq*^*kg41*^ defect is its lack of early motility at 16 ss, we investigated its neuronal differentiation. From 24 hpf onward, homozygous *sfpq*^−/−^ embryos show defects in axonal tracts in discrete areas of CNS and peripheral nervous system (PNS), with lack of posterior and supra-optic commissures and reduced inter-rhombomeric commissural axons ([Figures 2](#fig2){ref-type="fig"}A--2D). These also show defects in the axonal projections of both cranial ([Figures 2](#fig2){ref-type="fig"}E and 2F) and spinal cord MNs ([Figures 2](#fig2){ref-type="fig"}G--2P).Figure 2Axonogenesis Is Affected in *sfpq*^−/−^ EmbryosLateral (A, B, and G--P) and dorsal (C--F) views, anterior to the left, of zebrafish brain at 32 hpf (A and B) and spinal cord at 24--56 hpf.(A and B) *sfpq;Tg(dlx4.6:gfp)* embryos. Lack of supra-optic commissure (white arrow) and posterior commissure (white arrowhead) in coma (n = 8/32) is revealed by acetylated tubulin staining.(C and D) Dorsal view, anterior to the left of acetylated tubulin staining showing hindbrain disorganized axonal tracks in *sfpq* mutant (D; green arrowhead, n = 8) compared to siblings (C; n = 26).(E and F) Dorsal view, anterior to the left of GFP^+^ motor neurons in *sfpq; Tg(isl1:gfp)* siblings (E) and mutant (F), showing cranial motor neuronal clusters lacking axonal projections in the mutant (red arrowhead, n = 7).(G--N) Lateral view, anterior to the left, of confocal live imaging, showing temporal defect in axonogenesis in the majority of spinal motor neurons in a mutant (H, J, L, and N; n = 14) compared to a sibling (G, I, K, and M; n = 42) in the *Tg(mnx1: gfp)* background.(O and P) Lateral view, anterior to the left, of SV2 antibody staining of siblings (O) and *sfpq* null mutant (P), showing pre-synaptic protein in the few axons formed in *sfpq* mutants (n = 9). Scale bar, 100 μm.

The *sfpq*^*kg41*^ anterior spinal motor axons do occasionally manage to form and exit normally the spinal cord, neuronal behavior more readily observed in the *Tg(Xla.Tubb2b:Hsa.MAPT-GFP)*^*zc1*^ background, expressing a GFP-tagged microtubule-associated Tau protein in neurons, indicating that Tau overexpression has some beneficial effect in sfpq^kg41^ neurons. In this transgenic background, around 15% of homozygous mutants form anterior axons with neuro-muscular junctions (NMJs) and can generate some movements ([Movie S2](#mmc3){ref-type="supplementary-material"}). In all other backgrounds, most anterior MNs do not progress, stalling at the horizontal myoseptum and either stop there or branch excessively with poor progression along the somitic mass ([Figures 2](#fig2){ref-type="fig"}G--2N). Immunostaining with α-bungarotoxin (α-btxn; data not shown) and pre-synaptic SV2 shows normal pre- and post-synaptic pre-patterning in the mutant ([Figures 2](#fig2){ref-type="fig"}O and 2P; data not shown). However, the mutants never form mature NMJs. The motor axon defect of the mutant is not due to cell death, as healthy MN cell bodies are found until day 4 (GFP^+^ in [Figures 2](#fig2){ref-type="fig"}G--2N) and the mutants lacking p53 (thereby devoid of cell death; [@bib64]) still exhibit severe axogenesis defects ([Figures S2](#mmc1){ref-type="supplementary-material"}J--S2Q).

Somitic muscle differentiation occurs normally in the *sfpq* mutant, with typical V-shaped somitic boundaries, proper differentiation of both slow and fast muscle, and formation of sarcomeres ([Figures S2](#mmc1){ref-type="supplementary-material"}R--S2Y). The absence of axons in the vast majority of MNs, without initial defects in muscle differentiation, indicates that the primary defect is in the MNs.

Mosaic experiments ([Figure 3](#fig3){ref-type="fig"}) further demonstrate that *sfpq* is cell-autonomously required in neurons for their maturation. Cell transplantations in spinal cord territory of the neural plate at ∼70% epiboly show that *sfpq*^−/−^ MNs transplanted into wild-type embryos fail to show motor axon projections in 30 hpf host embryos ([Figures 3](#fig3){ref-type="fig"}G--3L and 3N; n = 8). Transplanted *sfpq*^−/−^ ventral neuro-progenitors do not show significant change in motor to interneuron ratio ([Figure 3](#fig3){ref-type="fig"}M; isl1/isl2a staining; data not shown). Conversely, donor wild-type MNs form functional axons ([Figures 3](#fig3){ref-type="fig"}C, 3D, and 3N; n = 7), eliciting muscle twitching, in 30 hpf *sfpq*^−/−^ mutant embryos. The donor neurons show some expected late axonal deformation in the strongly affected 3 dpf mutants ([Figures 3](#fig3){ref-type="fig"}E and 3F).Figure 3Sfpq Is Required Cell Autonomously for Motor Axon DevelopmentHomotopic transplantation at 70%--80% epiboly of *sfpq*^−/−^; *Tg(mnx1:GFP)* and sibling *Tg(mnx1:GFP)* ventral spinal cord progenitors into wild-type or *sfpq*^−/−^ hosts.(A and B) Schematic of the transplants from donor (A) to host (B) embryo.(C, D, and G--L) Lateral view, anterior to the left (C, D, and G--J) or transverse (K and L) of 30 hpf zebrafish transplanted trunks, showing the transplanted mnx1+ neurons in green and all axons in red (acetylated tubulin staining).(E and F) Lateral view, anterior left of transplanted wild-type MNs (green) in early larvae (3 dpf) in wild-type (E) or *sfpq*^−/−^ (F) hosts.(M) Quantification of VeLD interneurons in transplanted clones at 30 hpf (value is number of interneurons/total number of transplanted neurons, number of embryos in box).(N) Quantification of axonal lengths of transplanted neurons at 30 hpf. Scale bar, 100 μm.

SFPQ Regulates a Specialized Set of Transcripts {#sec2.3}
-----------------------------------------------

To uncover the molecular complexity driving loss of motility in *sfpq*^*kg41*^, we analyzed the mutant transcriptome at onset of the phenotype. Nimblegen microarray transcriptome analysis, on triplicate samples of total RNA extracted from 50 *sfpq*^*−/−*^*;Tg(mnx1:GFP)* and sibling embryos at the 22 ss, shows 571 of the 38,489 probes differentially expressed (99% confidence level). The vast majority of these transcripts (566/571) were downregulated in the homozygous *sfpq* mutant, and only five were overexpressed ([Figure 4](#fig4){ref-type="fig"}A). Validation of the microarray data was achieved by qPCR on randomly picked downregulated transcripts ([Figure 4](#fig4){ref-type="fig"}B).Figure 4Sfpq Loss of Function Affects a Specific Set of Transcripts(A) Scattered plot of the expression level of the total probe sets in the array. The 38,489 dots represent total individual probes for genes or expressed sequence tags (ESTs). The gene expression level is expressed in relative arbitrary units of fluorescence intensity on a logarithmic scale. Genes whose expression level is identical between the two groups lie on the diagonal line and the non-identical ones lie outside of the two lines parallel to the central diagonal purple line. The dots positioned above the upper diagonal line represent probe sets that are upregulated and the dots appearing below represent probe sets that are downregulated in the mutants as compared to siblings. Black dots represent those 571 probes with expression level at least 2-fold significantly different (p \< 0.05, moderated t test) between *sfpq*^+/−;+/+^*;* (*Tg:mnx1 gfp*) and *sfpq*^−/−^*;*(*Tg:mnx1 gfp*) embryos. A high correlation (R^2^ = 0.98) was observed for the linear regression performed on the gene set.(B) Validation of microarray results by qRT-PCR performed on randomly picked downregulated transcripts. The gene expression data from microarray and qPCR exhibited high correlation (Spearman's rho test; r(6) = 1, p = 0.01). Statistical comparison was performed using paired t test with Bonferroni correction for multiple comparisons. Fold change is expressed as the ratio between the linear expression levels of *sfpq*^+/−;−/−^*;* (*Tg: mnx1 gfp*) and *sfpq*^−/−^*;*(*Tg:mnx1 gfp*) samples and negative value represents downregulation of gene expression.(C) GO analysis of the differentially expressed genes.(D) Analysis of number of splice variants in whole transcriptome and SFPQ-dependent transcriptome. The SFPQ-dependent genes are substantially enriched for high numbers of splice variants (one-sided Wilcoxon-Mann-Whitney rank-sum test with continuity correction, p = 2.51 × 10^−26^).

ArrayStar analysis with the ZFIN gene annotation file provided annotation with gene ontology (GO) terms for only 8% (3,043 probes) of the whole chip and 7% (41 probes) of the SFPQ differentially expressed set (DES). With the customized gene annotation file generated (see [STAR Methods](#sec4){ref-type="sec"}), 76% (29,364 probes) of the chip was mapped to gene identities and 70% (26,798 probes) provided GO terms for the total set on the array. Of the DES, 81% (461 of the 571 probes) were mapped to gene symbols ([Table S1](#mmc1){ref-type="supplementary-material"}) and 74% (424 probes) of these are associated with GO terms ([Table S2](#mmc1){ref-type="supplementary-material"}). Of the five upregulated in the DES, only three are mapped to gene symbols. Out of the 26,798 total annotated probes, a total of 16,745 whole chip were annotated with GO terms. In total, 14 of the 59 GO terms at level 2 of the GO term hierarchy were enriched in the annotated array (p \< 0.05 after multiple testing correction; [Figure 4](#fig4){ref-type="fig"}C). Considering all levels of hierarchy, only 192 of the 8,624 GO terms represented in the total annotated array set were found enriched in the DES. These identified an unambiguously specific enrichment for molecules involved in cell adhesion, cell junctions, neuronal/synaptic structures, glutamate, and Wnt signaling ([Figure 4](#fig4){ref-type="fig"}C; [Table S2](#mmc1){ref-type="supplementary-material"}). Moreover, the three upregulated transcripts (*pard3*, *arvcfb*, and *dgat1*) are involved in cell adhesion ([@bib34]), cell polarity ([@bib68]), adherens junction complexes ([@bib22], [@bib47]), and dendritic spine morphogenesis ([@bib84]). Finally, 21% of the SFPQ transcriptome code for proteins identified as part of the synaptic proteome. The mutants undergo a substantial downregulation of neuronal-specific transcripts (genes listed in [Figure S4](#mmc1){ref-type="supplementary-material"}) despite an increase in neuronal populations (ectopic neurogenesis in rhombomeric boundaries; [Figure 1](#fig1){ref-type="fig"}). Finally, when compared with the whole-genome transcriptome, the differentially expressed set is substantially enriched for alternatively spliced transcripts and transcripts containing multiple, longer than average introns ([Figure 4](#fig4){ref-type="fig"}D; data not shown). The enrichment in transcripts with long introns is reminiscent of the findings showing a preference of TDP43 and FUS for binding to transcripts with long first introns ([@bib41]).

Non-nuclear Localization of Splicing Factors and Introns in Developing Neurons {#sec2.4}
------------------------------------------------------------------------------

Using antibodies, we assessed SFPQ protein localization in wild-type and maternal proteins in the mutant. In line with the reported role of SFPQ in many nuclear functions, we found robust nuclear staining throughout zebrafish development, with systematic enhanced expression in nuclei of post-mitotic neurons throughout development ([Figures 5](#fig5){ref-type="fig"}A and 5D--5F). Moreover, protein detection was unexpectedly found in variable levels in motor axons (arrows in [Figures 5](#fig5){ref-type="fig"}B, 5D, and 5F) and discrete axonal and dendritic populations throughout the CNS. Whole mount and western blot show that no detectable SFPQ protein was found in the mutant after the 12 ss (data not shown), showing that maternal contribution stops by that stage.Figure 5SFPQ Protein Is Found in Axons, with Unprocessed RNA Targets and Spliceosome Component U1 snRNP70Transverse single confocal sections of 24 hpf (A, N, and O) and 48 hpf (B--M) forebrain (A and I--K) or spinal cord dorsal to the top (G, H, L, and M) or to the left (B--D), and lateral view of head, anterior to the left (E and F).(A--F) SFPQ protein expression shown by antibody staining (A--D) or GFP-tagged ectopically expressed protein (E and F). Identity of red, green, and blue staining is labeled on bottom right corner of each picture. Arrow shows axonal localization.(G--K) Localization of first alternative introns (in red) of SFPQ-dependent transcripts, *bcas3* (G and H), and *gnao1a* (I--K). Axons are stained by acetylated tubulin antibody in green.(L and M) High-resolution imaging of *bcas3* intron detection (L; red) in motor axons stained with acetylated tubulin antibody (M; green).(N and O) Double antibody staining of U1 snRNP70 proteins (N) with acetylated tubulin (O; merged channels) in spinal axons. Arrows are pointing to motor axons. Scale bar, 25 μm.

In order to look at the dynamics of protein localization in live zebrafish, we designed a functionally active GFP-tagged version of zebrafish *sfpq*. Confirming the antibody results, we have found that injection of z-SFPQ-GFP DNA leads to nuclear GFP expression, including bright nuclear foci, in all cell types and GFP detection in neurites of some neuronal populations, including MNs ([Figures 5](#fig5){ref-type="fig"}E and 5F).

Together with the downregulation of neuronal and synaptic transcripts in the *sfpq*^−/−^ zebrafish mutant, this supports the possibility of a non-nuclear function for SFPQ, related either to the transport of mRNA and/or pre-RNA, or to non-nuclear RNA processing events. To begin to discriminate between these possibilities, we assessed whether SFPQ-regulated transcripts were present in any unprocessed form in wild-type neurites. We chose to screen for the first alternative intron of a series of SFPQ-dependent neuronal transcripts. Introns were detected in neurites of wild-type embryos for 11 of 36 neuronal transcripts tested ([Figures 5](#fig5){ref-type="fig"}G--5M; [Table S3](#mmc1){ref-type="supplementary-material"}; at least 20 embryos per probe), but undetectable in homozygous sfpq mutants, suggesting that unprocessed transcripts may be abundant in specific neuronal populations and degraded, or not produced, in *sfpq* mutants. The axonal presence of intronic sequences is coincidental with detection of the core spliceosome protein snRNP70 (U1 snRNP), expressed in neurites across the whole of the CNS, including motor axons ([Figures 5](#fig5){ref-type="fig"}N and 5O; n = 32).

Non-nuclear SFPQ Rescues the Motor Axon Defect of the sfpq Mutant {#sec2.5}
-----------------------------------------------------------------

To assess whether the presence of SFPQ in axons is functionally relevant to MN function, we tested whether a cytoplasmic form of the protein was able to rescue the neuronal defect in the mutant. We made use of the human truncated protein lacking the C-terminal non-canonical nuclear localization signal (NLS), previously shown to prevent SFPQ nuclear import without affecting the structure and functional domains ([@bib17]). We found that injection of the RNA coding for this cytoplasmic form is able to restore both motor axon growth and movement in the homozygous *sfpq* mutant ([Figures 6](#fig6){ref-type="fig"}E--6L; [Movie S3](#mmc4){ref-type="supplementary-material"}; n = 37 homozygous embryos). Deletion of a second putative minor NLS sequence sitting in the coiled-coil domain (see [Figure 1](#fig1){ref-type="fig"}E) affected the protein structure and function ([@bib43]; data not shown). The motor rescue can't be explained by residual nuclear localization of hsfpqΔNLS, as the threshold required for rescue by injection of the wild-type form is well above detection level ([Table S4](#mmc1){ref-type="supplementary-material"}) and mosaic co-injection of pmnx1:GFP and pCS2:hsfpqΔNLS DNA in the mutant shows axonal expression of SFPQ in restored axons, with nuclei lacking detectable hSFPQ protein ([Figures 6](#fig6){ref-type="fig"}E and 6F; n = 14; [Figure S3](#mmc1){ref-type="supplementary-material"}A).Figure 6Non-nuclear Sfpq Rescues Loss of Transcripts and Axonal Phenotype in the *coma* MutantLateral view of 30 hpf zebrafish (A--D) and spinal cord (G--L), anterior to the left.(A--D) General morphology of *sfpq*^−/−^ (A); *sfpq*^+/−^ siblings (B); *sfpq*^−/−^ injected with *GFP-hsfpqΔNLS* (C) and *sfpq*^+/−^ injected with *GFP-hsfpqΔNLS* (D). Insets showing localization of the human GFP-tagged protein in early ss embryos, CAAX-Cherry in red.(E) Whole-mount detection of SFPQ (red) in a 28 hpf *sfpq*^−/−^ mutant, injected at one-cell stage with pmnx1:GFP and pCS2:hsfpqΔNLS DNA, expressing these mosaically. Arrow shows motor axon. Note the negative nuclei (arrowhead).(F) Measurement of ventral motor axon length in siblings and homozygous mutant uninjected or injected with RNA (DNLS) or DNA (MOSAIC DNLS) coding for hSFPQΔNLS. For the controls and RNA injections, the ventral motor axons were measured in five embryos over five-somite length upstream of the cloaca. For mosaic DNA-injected sample, measures were done only in seven homozygous mutants, in the same trunk area for the rare SFPQ+ neurons.(G--L) Lateral view, anterior to the left of spinal cords, showing rescue of the axonal defect both in the anterior (G and J) and posterior (H and K) trunk of *sfpq*^−/−^;*Tg (mnx1:GFP)* by injection of the ΔNLS human SFPQ. Sibling axons are unaffected by the injection (I and L).(M) qPCR results for six out of ten DES transcripts from 32 hpf siblings and *sfpq*^−/−^ mutant embryos uninjected or injected with human ΔNLS *sfpq* RNA. Bars show expression fold changes compared to the expression level of the transcript in uninjected sibling embryos taken as reference. The four transcripts not plotted did not show any improvement after ΔNLS rescue.

The motor rescue obtained with the hsfpqΔNLS is accompanied by a strong morphological phenotype (short body axis and variable cyclopia) likely induced by cytoplasmic accumulation of SFPQ in the developing embryo. This phenotype is observed in homozygous, but not in heterozygous and wild-type siblings ([Figures 6](#fig6){ref-type="fig"}A--6D). The absence of phenotype in siblings is explained by the presence of GFP-hsfpqΔNLS in their nuclei, due to correct transport elicited through complex with endogenous SFPQ (inset in [Figure 6](#fig6){ref-type="fig"}D). Finally, qPCR done on extracts from control and hsfpqΔNLS-injected *sfpq*^+/−^ progeny for ten randomly picked neuronal SFPQ-dependent transcripts shows rescue of expression level for six of these by the ΔNLS injection ([Figure 6](#fig6){ref-type="fig"}M), demonstrating a substantial impact of the cytoplasmic protein on transcript levels. The six transcripts rescued are all connected to axonal and synaptic functions, and we found intron retention for three of them (bcas3, nbeaa, and tnr) in wild-type neurites. All together, these results show that cytoplasmic SFPQ is sufficient to establish motor connectivity and to protect key axonal transcripts from degradation.

Human SFPQ Mutations Found in ALS Patients Affect SFPQ Localization and Induce Abnormal Motor Axon Morphology {#sec2.6}
-------------------------------------------------------------------------------------------------------------

Exome sequencing of the human *SFPQ* gene (Refseq ID [NM_005066](ncbi-n:NM_005066){#intref0010}) in DNA samples from 151 index familial ALS (fALS) patients revealed two independent sequential missense mutations, N533H (c.1597A\>C, we have called hsfpqN) and L534I (c.1600C\>A, we have called hsfpqL). These mutations affect adjacent residues within the second coiled-coiled domain of the molecule (residues 528--555; [Figure 7](#fig7){ref-type="fig"}M) in a region fully conserved from fish to mammals ([Figure S3](#mmc1){ref-type="supplementary-material"}C). This coiled-coil domain has been identified as being essential for the polymerization of SFPQ dimers, paraspeckle formation, and transcript processing ([@bib43]). From the ExAC database, we know that many missense variants are found in normal individuals ([Figure 7](#fig7){ref-type="fig"}L). Both mutations are present in heterozygous form in the patients and are absent from all public polymorphism databases (∼66,000 individuals), including dbSNP142, 1000 Genomes (<http://www.internationalgenome.org/>), the Exome Variant Server (<http://evs.gs.washington.edu/EVS/>), and ExAC (<http://exac.broadinstitute.org/>). Unfortunately, no family members were available from these kindreds for segregation analysis.Figure 7Human Mutations Affect SFPQ Localization and Motor Development in the Zebrafish(A--K) Lateral (A--F) and transverse (G--K, N, and O) views of the spinal cord in *sfpq*^−/−^ mutant (A, B, and H), siblings (C and G), and homozygous mutant rescued by wild-type human *Sfpq* (D and I) or L534 (E, J, and O) or N533 (F and K) mutant human *Sfpq*.(L) Distribution of SFPQ variants in all exome-sequenced human individuals. In red, the position of the variants only found in fALS patients.(M) Schematic of the wild-type hSFPQ protein and the seven variants cloned and tested in double-blind rescue experiments in the Tg(mnx1:GFP) background. S8N (c.23G\>A) is present in 4 SALS and 24 ExAC samples, showing a modest enrichment in SALS (p = 0.029, two-tailed Fisher's test). P51L (c.152C\>T) is private to a single SALS patient and absent from all controls. M469V (c.1405A\>G) is in a single SALS patient and twice in ExAC (p = 0.071). A515V (c.1544C\>T) and A515T (c.1543G\>A) are in two and one ExAC normal individuals, respectively, and are located in the coiled-coil domain close to the two FALS variants we identified.(N and O) Close-up of the motor axon and its environment, stained for SFPQ in red and GFP in green in the *sfpq*^−/−^*; Tg(mnx1:GFP)* rescued by injection of the human (N and N′) or L-mutated form (O and O′). Arrowheads show localization of SFPQ in motor axons.(P) Quantification of the α-SFPQ red fluorescent signal in motor axons on confocal stacks, for five pairs of motor axons per 48 hpf embryo stained with SFPQ antibody. Measurement was done in no less than 30 (maximum, 46) embryos per variant injected. Injection is done in *sfpq*^+/−^;*Tg(mnx1:GFP)* incross progeny. The embryos showing poor signal intensity were genotyped and were all homozygous mutants.(Q) Quantification of the length of ventral motor axons. Measures were made for five segments per 48 hpf embryo (five somites anterior to the cloaca) on confocal stacks, using FIJI Single Neurite Tracer in no less than 28 (maximum, 41) embryos per variant injected. Injection is done in *sfpq*^+/−^;*Tg(mnx1:GFP)* incross progeny. The embryos showing shorter axon length were genotyped and were all homozygous mutants. Asterisks indicate highly significant reduction in axon lengths compared to wild-type (pairwise ANOVA, ^∗∗∗^p \< 0.0001). The two significantly different variants show same difference when comparing pairwise to the other variants. All other variants are not significantly different from wild-type.(R) Quantification of ectopic ventral motor branching. Measures were made for five segments per 48 hpf embryo (five somites anterior to the cloaca) on confocal stacks using FIJI Single Neurite tracer in no less than 28 (maximum, 41) embryos per variant injected. Injection is done in *sfpq*^+/−^;*Tg(mnx1:GFP)* incross progeny. The embryos showing excessive branching were genotyped and were all homozygous mutants. Asterisks indicate significance (pairwise ANOVA, ^∗∗∗^p \< 0.0001 and ^∗∗^p \< 0.001) compared to wild-type. The two significantly different variants show same difference when comparing pairwise to the other variants. All other variants are not significantly different from wild-type.

To evaluate the effect of human mutations on the protein function, we tested whether a series of human variants was able to rescue the zebrafish null mutant. We injected mRNA of wild-type or variant alleles and characterized SFPQ protein localization, axonal morphology, and larval motility. In addition to the two ALS-linked mutations, we cloned five other missense variants, choosing those (from ALSDB and ExAC databases; [Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C) that cover various areas of the gene, some only found in normal individuals, others found in both ALS and normal samples ([Figure 7](#fig7){ref-type="fig"}M). We quantified the degree of rescue after injection of eight different human transcripts in replicated double-blind experiments. We found that all SFPQ variants are able to broadly rescue the mutant phenotype (including heart defects). Larval motility is normal from its onset and MNs develop at the same pace as wild-type (data not shown). However, when quantifying axon length and shape, we find that the rescued motor axons are often shorter and branch excessively in the hsfpqN and L-injected mutant embryos ([Figures 7](#fig7){ref-type="fig"}A--7K, 7Q, and 7R), but not in any injected with other missense variants. Correlated to these defects, detection of SFPQ protein levels is severely reduced in the motor axons of hsfpqN and L-injected mutant embryos and at normal levels in mutants rescued with wild-type and the five other hsfpq variants ([Figure 7](#fig7){ref-type="fig"}P). Levels are rarely reduced in the proximal axonal segment near the spinal exit but are pronounced distally ([Figures 7](#fig7){ref-type="fig"}N--7O′), indicating that ALS-linked mutations in the coiled-coil domain of the protein may impair the axonal transport of SFPQ.

Altogether, our results show that axonal SFPQ is required for normal motor axonal development, connectivity, and thereby motility in zebrafish. Furthermore, two fALS-linked mutations, lying within the coiled-coil domain of SFPQ, significantly impede its distribution into the distal axon and affect motor axonal branching in zebrafish, showing the importance of the coiled-coil domain in axonal localization and normal motor axon development. Perturbation of motor axon morphology in *sfpq* mutant embryos rescued by fALS-linked variants may suggest a causal link between these two mutations and the human motor degenerative disease. However, segregation data and additional cases carrying mutations in the same residues are needed to support this possibility further.

Discussion {#sec3}
==========

Our study shows that the ubiquitously expressed multi-functional splicing factor SFPQ is functionally required for expression of a restricted set of transcripts during development and carries an essential non-nuclear function in developing motor axons. Moreover, we identify two human *sfpq* point mutations affecting the protein function in zebrafish MNs. We show that these human mutated proteins are affected in their ability to localize in motor axons and to elicit normal motor axon morphology in an endogenous SFPQ null background, while still enabling NMJ formation and normal motility, indicating a likely role for axonal SFPQ in human motor function and a possible developmental origin to some forms of motor degeneration.

SFPQ in RNA Transport and Cytoplasmic Processing {#sec3.1}
------------------------------------------------

SFPQ has been previously described as associated with transport granules in cell culture ([@bib33]) and very recently shown to be required directly or indirectly for transport of RNA regulon in sensory neurons ([@bib14]). Our study provides the first in vivo evidence that the cytoplasmic pool of SFPQ is required for axon development through regulation of RNA transport and/or processing in MNs. As transport granules are indeed found to be essential for neuronal function ([@bib33]), one possible requirement of SFPQ in axon may be transport, as suggested by Cosker and colleagues in cultured sensory neurons. However, we found that complete loss of SFPQ function, such as the one they induced in sensory neurons, severely affects transcripts coding for transport proteins such as dynein chains ([Table S1](#mmc1){ref-type="supplementary-material"}), making it difficult to distinguish direct from indirect requirement in transport. More compelling is the ability of our cytoplasmic version of SFPQ to rescue motor activity and restore a subset of neuronal transcripts in the zebrafish mutant, strongly demonstrating a cytoplasmic role in transcript maintenance. One such function may be to protect transcripts (intron retaining or not) from nonsense-mediated decay ([@bib82]). Intron retention has been previously reported in neurons ([@bib4]). Our study shows intron retention in developing axons, and detection of U1 snRNP70 spliceosome protein, opening a third possibility: SFPQ may be involved in some form of extra-nuclear processing. Tissue-specific alternative splicing has long been recognized as a powerful source of molecular diversity. This mechanism is particularly important in the nervous system, where isoform variation is involved in synapse formation, neurotransmission, synaptic plasticity, cell recognition, and ion channel function ([@bib24], [@bib36], [@bib54]). While post-transcriptional regulation commonly occurs in the nucleus, recent studies ([@bib4], [@bib6], [@bib23], [@bib37]) indicate that modification of 3′ UTR sequences, alternative polyadenylation, and even splicing may be in some situation cytoplasmic, which opens the possibility of sophisticated local axonal and dendritic RNA processing occurring within developing and mature neurons.

The possibility that a subset of transport granules may be specialized for local processing of specific types of introns is a very attractive idea in the context of neurons. Many of the neuronal populations controlling our behaviors have the cell nucleus tens of centimeters away from the site of active synapses. The option of local splicing would be an advantageous mechanism to generate alternative transcripts known to be required for the rapid modulation of synaptic connectivity and other neuronal functions. Our SFPQ mutants are ideal models to now address these possibilities.

SFPQ and Neurodegenerative Disorders {#sec3.2}
------------------------------------

SFPQ plays a key role in processing pre-mRNA coding for proteins that are central to several neurodegenerative conditions. It regulates tau pre-mRNA splicing by suppressing Tau exon 10 inclusion and thus regulating the balance of Tau4R/Tau3R ratio ([@bib61]), associated with tauopathies such as frontotemporal dementia (FTD; [@bib7], [@bib12], [@bib26], [@bib28], [@bib29], [@bib31], [@bib46], [@bib70]). SFPQ is expressed at higher levels in the hippocampus and cortex of human brain, the regions principally affected by tauopathy ([@bib61]). The nucleo-cytoplasmic redistribution of SFPQ under pathological conditions is similar to that reported for the RNA-binding proteins, TDP-43 and FUS, in ALS and FTLD ([@bib53], [@bib80], [@bib81]). Microarray data analysis of transcripts in cortical neurons of Alzheimer's disease (AD) patients identified upregulated *SFPQ* expression ([@bib27]). In addition to neurodegenerative diseases, SFPQ is also associated with other neurodevelopmental disorders. Recent studies have associated SFPQ and its partner NONO to autism spectrum disorders and intellectual disability, and found SFPQ upregulated in the frontal cortex of bipolar disorder patients ([@bib52], [@bib42]).

Our work showed U1-snRNP70 and SFPQ together in motor axons. Intriguingly, two very recent publications showed that this U1 spliceosome protein functionally interacts with the ALS-causative RNA processing protein FUS ([@bib83], [@bib72]). In these studies, the expectation is that these interact inside the nucleus. However, we find partial co-localization of SFPQ with FUS in axons and FUS has now been found enriched in synapses, suggesting that the synaptic dysfunction observed in FUS mutant may be due to local axonal/synaptic loss of function.

Our work puts a new light on these recent findings, shifting the focus onto cytoplasmic interaction of these proteins and RNAs in the normal context and potential dysregulation of these interactions in neurodegenerative disorders. Neurodegeneration has mostly been understood as caused by sequestration of splicing factors and/or other proteins in cytoplasmic aggregates that induce loss of essential protein function in the nucleus and/or detrimental toxicity in the cytoplasm. However, our data support the intriguing possibility that some neurodegenerative and neurodevelopmental disorders may arise from progressive loss of a cytoplasmic RNA processing function in axons and synapses, triggered during development. Such a mechanism is suggested by a very recent study showing that HNRNP2AB1 is shaping the splicing landscape of neurons, a role specifically affected by ALS-associated mutations in this gene ([@bib48]). Neuronal homeostasis may be dependent upon a complex balance between nuclear and extra-nuclear RNA processing events controlled by proteins such as SFPQ, HNRNPA2, U1 snRNP70, and FUS, a balance that, when disturbed, may contribute mechanistically to a wide range of neurological disorders.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**acetylated α-tubulinSigma, Mouse IgG2bCat\#T6793; RRID: [AB_477585](nif-antibody:AB_477585){#intref0030}GFPAmsbio, Rabbit IgGCat\#TP401; RRID: [AB_10013661](nif-antibody:AB_10013661){#intref0035}F59DSHB, Mouse IgG1Cat\# f59; RRID: [AB_528373](nif-antibody:AB_528373){#intref0040}F310DSHB, Mouse IgG1Cat\#F310; RRID: [AB_531863](nif-antibody:AB_531863){#intref0045}phosho-Histone H3Millipore UK, Rabbit-IgGCat\#06-570; RRID: [AB_310177](nif-antibody:AB_310177){#intref0050}ZO-1Invitrogen, mouse IgG1Cat\#339100; RRID: [AB_87181](nif-antibody:AB_87181){#intref0055}HuC/DMolecular ProbesCat\#A21271; RRID: [AB_221448](nif-antibody:AB_221448){#intref0060}α-bungarotoxinInvitrogen, Alexa Fluor 488 conjugatedCat\#B13422; RRID: [AB_2636927](nif-antibody:AB_2636927){#intref0065}snRNP70AvivaSysBioN/ASFPQAbCam38148Cat\#ab38148; RRID: [AB_945424](nif-antibody:AB_945424){#intref0070}FastDigest ClaIThermo ScientificCat\#FD0144CAAX-mcherry RNASean Megason (Scott Fraser) Caltech, CA 91125N/ATRIZOL RNA isolation reagentInvitrogenCat\#10296010DNaseIAmbion TURBO DNase Free kitCat\#AM1907**Bacterial and Virus Strains**Zebrafish *sfpq* complete cDNASource BioscienceIMAGE: 6962536pDONR221 entry cloneGateway, InvitrogenCat\#12536017**Critical Commercial Assays**mMessage Sp6 kitAmbionCat\#AM1340The Gateway cloning systemInvitrogenCat\#18248013Quickchange II Site-Directed Mutagenesis KitAgilent TechnologiesCat\#200523TOPO TA Expression KitInvitrogenK4810-01High pure RNA isolation kitRocheCat\#11828665001SuperScript Double-Stranded cDNA Synthesis KitInvitrogenCat\#11917020First strand CDNA synthesis kitThermo Scientific (Molecular Biology)Cat\#K1612Qiaquick PCR purification kitQIAGENCat\#28104SYBR Green I Master kitRocheCat\#04707516001NimbleGen 12 × 135 k zebrafish gene-expression arraysRoche Diagnostics LimitedCat\#05545862001**Deposited Data**Microarray DataArrayExpressArrayExpress: [E-MTAB-5559](array-express:E-MTAB-5559){#intref0075}**Experimental Models: Organisms/Strains**Zebrafish: *Tg(isl1:GFP)rw0*[@bib30]ZFIN ID: ZDB-TGCONSTRCT-070117-161Zebrafish: *Tg(1.4dlx5a-dlx6a:gfp)ot1*[@bib21]ZFIN ID: ZDB-TGCONSTRCT-070117-17Zebrafish: *Tg(TOP:gfp)w25*[@bib16]ZFIN ID: ZDB-TGCONSTRCT-070117-137Zebrafish: *Tg(Bactin:HRAS-EGFP)vu119*[@bib13]ZFIN ID**:** ZDB-TGCONSTRCT-070117-75Zebrafish: *Tg(Xla.Tubb2b:Hsa.MAPT-GFP))zc1*[@bib76]ZFIN ID: ZDB-TGCONSTRCT-070117-135**Oligonucleotides**Primers for qRT-PCRThis paper[STAR Methods](#sec4){ref-type="sec"}; qRT-PCR**Software and Algorithms**ArrayStar4 softwareDNASTAR, Madison, USA<https://www.dnastar.com>Gene Annotation: ZFINrelease 9, April 24, 2013<https://zfin.org/>ENSEMBLrelease 71<http://www.ensembl.org>Gene OntologyMay 7, 2013<http://www.geneontology.org>Rversion 3.1.0<https://www.r-project.org>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Corinne Houart (<corinne.houart@kcl.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Zebrafish Embryos Maintenance {#sec4.3.1}

Zebrafish (*Danio rerio*) were maintained at 28°C on a 14 hr light/10 hr dark cycle ([@bib5]). Embryos collected were cultured in fish water containing 0.003% 1-phenyl-2-thiouera to prevent pigmentation and 0.01% methylene blue to prevent fungal growth.

ENU mutagenesis was performed as previously described ([@bib69]). The *sfpq* heterozygous mutant was crossed with a set of GFP transgenic lines (*Tg(isl1:GFP)rw0* ([@bib30]), *Tg(1.4dlx5a-dlx6a:gfp)* ([@bib21]), *Tg(TOP:gfp)w25*([@bib16])*, Tg(Bactin:HRAS-EGFP)vu119* ([@bib13]), *Tg(Xla.Tubb2b:Hsa.MAPT-GFP))zc1*([@bib76]) and *Tg(mnx1:GFP)ml2/+(AB)* (also known as Tg(*HB9: gfp*); [@bib19]). Embryos collected from incross of heterozygous mutant carriers from these transgenic mutant lines were selected for the transgene based on GFP fluorescence.

The animal experimentations have been authorized by KCL Ethic Review Committee and under the HO license 70/7577.

### Recruitment of Human Subjects {#sec4.3.2}

Patients were recruited from the Local ALS Clinic of Kings College London, Denmark Hill, UK and through neurogenetic clinics at Concord Hospital, Sydney, Australia, under informed written consent. Patients were diagnosed with definite or probable ALS according to El Escorial criteria, and had a family history of ALS and/or FTD.

Method Details {#sec4.4}
--------------

### Genotyping of sfpq mutant {#sec4.4.1}

The homozygous mutant embryos were selected from offspring of incross of heterozygous carriers based on the brain and motility phenotype at 28 hpf. Genomic DNA was separately extracted from 300 homozygous embryos and same number of siblings by standard protocol. The mutation was mapped by PCR amplification with random amplified polymorphic DNA (RAPD) and simple sequence length polymorphism (SSLP) markers on a section of zebrafish chromosome 19. Linkage analysis and subsequent candidate gene approach indicated '*sfpq'* as the gene mutated in the ENU mutant under study ([@bib59]).

### Whole mount in situ hybridization and Immunohistochemistry {#sec4.4.2}

Whole-mount in situ hybridization was performed as described elsewhere ([@bib75]). The following antisense RNA probes were used: *pax2.1* ([@bib38]), *fgf8* ([@bib62]), *foxb1.2* ([@bib2], [@bib51]), *EphA4*^17^, *zash1a* ([@bib1]), *rfng* ([@bib11]), *lhx5* ([@bib77]) and *axin2* ([@bib8]). TUNEL (terminal deoxynucleotide (TdT) dUTP nick labeling) assay was performed using ApopTag peroxidase In situ Detection Kit (Chemicon Cat\# S7100) to identify apoptotic cells. Digoxigenin-labeled DNA fragments in the assay were detected by antibody conjugated to alkaline phosphatase (instead of anti digoxigenin-HRP recommended by manufacturer's protocol) and color reaction was carried out using NBT/BCIP.

Transgenic GFP embryos used for in situ hybridization with digoxigenin labeled antisense RNA probes were stained with Fast Red (Roche) prior to GFP immunostaining. Immunostaining was carried out as previously described ([@bib65]). Primary antibodies and dilutions used were as follows: acetylated α-tubulin (Sigma, Mouse IgG2b, 1:1000), GFP (Amsbio, Rabbit IgG, 1:500), F59 (mouse IgG1, 1:10), F310 (mouse IgG,1:10), phosho-Histone H3 (Millipore UK, Rabbit-IgG, 1:500), ZO-1 (Invitrogen, mouse IgG1,1:500), HuC/D (1:200; Molecular Probes), Alexa Fluor 488 conjugated α-bungarotoxin (10 μg/ml PBS, 30 min incubation, Invitrogen), snRNP70 (1:100, AvivaSysBio), SFPQ (1:300, AbCam38148). At least 20 embryos were used per experimental sample per probe and per genotype. Images were acquired with a Nikon eclipse E800 microscope for in situ hybridization and confocal laser scanning microscope (Nikon Eclipse 80i) for immunostaining and time lapse imaging. Images were adjusted for brightness and contrast using Adobe Photoshop 8.0 and cell count and videos were processed using ImageJ software. Cell counts of proliferating cells were performed by a person blind to the genotype of the embryos on Z stack image of WT and coma embryos. For statistical analysis, two-tailed Student's t test was performed using Microsoft Excel.

### Live imaging {#sec4.4.3}

Time-lapse study was performed to investigate the mutant axonogenesis defects by live imaging a *sfpq*^*−/−*^; *Tg(mnx1:GFP)* embryos from 20hpf until 72hpf. The primary motor axon initiates exit at 17hpf and reaches the target during the second day of embryonic development in WT. Images were taken every 10 min for up to 2h at different stages of growth on a Nikon E80 confocal microscope. The embryos were anesthetized in 0.02% tricaine, embedded in 1% low melting point agarose dissolved in E2 embryo medium in a 35 mm tissue culture plastic dish and filled with E3 medium for confocal imaging. The embryos were removed from the agarose after imaging, maintained in E2 embryo media at 28**°**C.

### Rescue experiments and localization of GFP-tagged SFPQ proteins {#sec4.4.4}

The IMAGE clone (IMAGE: 6962536) of zebrafish *sfpq* complete cDNA sequence in pCMVsport6.1 (Source Bioscience) was sequence verified and stored at --20°C. The plasmid DNA was linearized with FastDigest ClaI (ThermoScientific) and used as template for in vitro synthesis of capped *sfpq* mRNA using the mMessage Sp6 kit (Ambion). The mutant rescue was performed by injecting z-*sfpq* mRNA into one-cell stage embryos derived from the *sfpq−/−;Tg(mnx1:GFP)* incross and *sfpq−/−;Tg(isl1:GFP)* incross. The extent of the rescue was determined by assessing the brain phenotype, motility and the motor neuron expression at 36hpf. A minimum of 180 pg/embryo is required for full phenotypic rescue.

The Gateway cloning system (Invitrogen, Carlsbad, CA) and Tol2 kit ([@bib40]) was used to clone the full-length z*sfpq* cDNA to generate the expression constructs UAS-zSFPQ-GFP and Hs-zSFPQ-GFP. The GFP tagged human constructs, containing full length GFP-PSF and the GFP-PSF Δ 1-702 ([@bib17]), obtained from Prof. James Patton were subcloned into pCS2+ for in vitro transcription of wild-type *hsfpq* and *ΔNLShsfpq*. The human SFPQ L534I and N533H mutant forms were made by site directed mutagenesis according to the manufacturer's protocol (Quickchange II Site-Directed Mutagenesis Kit, Stratagene) using a Gateway pDONR221 entry clone containing WT full length coding SFPQ (Gateway, Invitrogen). These were then subcloned in pcDNA3.1 NT-GFP using the TOPO TA Expression Kit (Invitrogen K4810-01), by PCR amplification from pDonr221 with the primers sfpqORF5′: ATGTCTCGGGATCGGTTCCGG and sfpqORF3′: CTAAAATCGGGGTTTTTTGTTTGG and the Q5 High-Fidelity proofreading DNA Polymerase (NEB M0491S).

### Mutation screening of Human SFPQ {#sec4.4.5}

Exome sequencing was performed on 151 index cases from the UK (n = 87) and Australia (n = 64), with an average age-of-onset of 59 years and an average disease duration of 34 months. UK FALS cases were all Caucasian individuals from the South -East of London and Kent. FALS cases from Australia were predominantly of European ancestry. All samples were free from currently known ALS-associated coding mutations and the intronic C9orf72 GGGGCC repeat expansion. Samples were captured using either Nimblegen V3, Illumina TruSeq Exome Enrichment or Agilent SureSelectXT Human All Exon-V5-UTR probes and 100bp paired-end reads sequenced on an Illumina HiSeq-2000. Reads were assembled to the hg19 reference genome achieving an average of 115x coverage across all Refseq coding bases, and variants were called with 'SAMtools Mpileup'. Novel SFPQ variants which were absent from all public variant databases were confirmed by PCR from original stock DNA and directly sequenced using Big-Dye Terminator v1.1 chemistry and an ABI3130 genetic analyzer (Applied Biosystems Pty Ltd, Warrington, UK). Sequence chromatograms were analyzed for mutations using Sequencher 4.10 (Gene Codes Corporation, Ann Arbor, Michigan, USA).

### Spinal motor axon mosaic experiment {#sec4.4.6}

Progenies from incrosses of *sfpq+/−;Tg(mnx1:mGFP)* were injected with CAAX-mcherry RNA at one cell stage (donor embryos). Mosaic embryos were produced by homotopic and homochronic transplantation into wild-type hosts. Around 20 dorso-posterior epiblast cells collected from late gastrula stage donor embryo (80%--100% epiboly; collected by capillary suction around the posterior midline) were placed at the equivalent location in the same stage wild-type host embryo. The donor and host embryo were identified as *sfpq*^*−/−*^ or WT sibling based on the MHB and axonogenesis phenotype at 24hpf and identity confirmed by PCR at 36hpf after clonal analysis. Embryos with the transplants that led to the incorporation of the donor cells (mcherry+) in the ventral spinal cord and GFP-positive motor axons were selected for further analysis. Only 25% of the donor clones are homozygous for *sfpq.* We transplanted more than 120 embryos across different days. To assess the behavior of wild-type neurons in mutants, the same approach was taken with *Tg(mnx1:mGFP)* wild-type donors into host embryos from sfpq+/− crosses.

### DNA Microarray {#sec4.4.7}

A total of six set of embryos (three pools of 50 homozygous *sfpq;Tg(mnx1:GFP)* and WT sibling embryos) were fast-frozen in liquid nitrogen and stored at **−** 80°C until RNA extraction. All homozygous *sfpq* embryos exhibits impaired motility at 22hpf and this feature was used to segregate mutant embryos from WT siblings for the study. Total RNA was isolated using high pure RNA isolation kit (Roche). Quality and purity was assessed by Nanodrop absorbance ratios and by Agilent Bioanalyzer (BRC genomics core facility, KCL) and used for microarray analysis and subsequent quantitative RT-PCR experiments.

Six RNA pools of 10 μg of total RNA each were used to make double stranded cDNAs, synthesized using the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen). These were hybridized separately on NimbleGen 12 × 135 k zebrafish gene-expression arrays. The array contains 38,489 probe sets with up to 3 probes of 60-mer oligonucleotides per gene. The arrays represented at least 24,000 genes plus additional ESTs from multiple zebrafish tissues. The design of the array relied on gene and EST information from several sources; Ensembl 46 (August 2007, Zv7), RefSeq (September 2007), TIGR (Release 14.0), UniGene (Build 54), Vega 27, and ZGC (August 2007).

### RT-qPCR {#sec4.4.8}

Total RNA was extracted from pools of *sfpq*^*−/−*^*;Tg(mnx1:GFP)* and *sfpq*^*+/−; +/+*^*;Tg(mnx1:GFP)* embryos at 24hpf using TRIZOL RNA isolation reagent (Invitrogen). cDNA was synthesized (First strand CDNA synthesis kit, GE Healthcare) after treating the RNA isolated with DNaseI (Ambion TURBO DNase Free kit). Products were purified using Qiaquick PCR purification kit (QIAGEN). Reactions were performed using SYBR Green I Master kit (Roche) on a Stratagene MX3005P and data analyzed using MxPro software. Three independent biological replicates of the WT sibling and mutant pools were included in the analysis and all reactions were carried out in triplicates. Cycling parameters were as follows, 95°C 10 min for 1 cycle then 95°C 30 s, 60°C 30 s, 72°C 30 s for 40 cycles then 95°C 60 s, 60°C 30 s, 95°C 30 s for all primer sets. Primer sequences used are as follows: *bcas3* (F -- 5′ GCATGTGGAGATAATGCCCA 3′, R -- 5′ CAGTCCTTCGCCATCAGAAT 3′); *fstlb* (F -- 5′ TTCCTCAACTGCCTGAAACC 3′, R - 5′ TTCCTCAACTGCCTGAAACC 3′); *dlg1* (F -- 5′ TTGGCTGTGAATGCTGTTTG 3′, R -- 5′ GGCTCCCTTGTGATCTCATC 3′); *crim1* (F -- 5′ CCACACTGTCCAGATGATCC 3′, R -- 5′ CTCGTCCATGTACGTCTTCC 3′); *nbeaa* (F -- 5′ GGTGATAACGGTGTTGTGGA 3′, R -- 5′ CCCTGAACTGAGAGGAAACG 3′); *tnr* (F -- 5′ GGCTCAGTCAACACAGGAAT 3′, R - 5′ TCTCTTGGCTTCCTCTCACT 3′); *smyd3* (F -- 5′ AAACTGCCTGTCAAAGTTGC 3′, R -- 5′ TCCGTCTTCTCCTCACTCAT 3′); *gpc3* (F -- 5′ GCAAAATGGAGGAGCGTTAC 3′, R -- 5′ GCATCAGAGCCCAGAATGTA 3′); *edil3* (F -- 5′ CCAGCAGATAACAGCCTCAT 3′, R -- 5′ TCTTTCCGTCATCGCTGTAG 3′) and *ef1a* (F -- 5 TTGAGAAGAAAATCGGTGGTGCTG 3′, R -- 5′ GGAACGGTGTGATTGAGGGAAATTC 3′). The expression levels of the genes selected were normalized to an endogenous control gene *ef1a*.

### Intronic whole mount in situ hybridization {#sec4.4.9}

Antisense probes against the sequences of intron 2 of the following twenty genes (ncam1b, igsf21a, nbeaa, gria3b, Hpca, gnao1a, cadm4, ank2b, gng7, cacng2a, oprl1, lrp1bb, bcas3, grip2b, TLN2, rbms3, fut8, Chrm3a, dbn1, ctnna2) were made from PCR amplified fragments (5′ primers containing the sp6 promotor sequence) using zebrafish genomic DNA as template. RNA probes of the genes were then made using the standard protocols. Whole mount in situ hybridization for the intronic genes were performed on 24h and 48h embryos using an *InSituPro* automated system (Intavis, Germany).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Gene Expression and Ontology Analysis {#sec4.5.1}

The gene expression level and folds changes calculated from six separate samples were normalized by quantile normalization and the gene expression values were generated by RMA (Robust Multichip Average) algorithm. The processed microarray data files received from the Nimblegen were subsequently analyzed using ArrayStar4 software (DNASTAR, Inc. Madison, USA). Technical replicates were all highly correlated (R^2^ \> 0.97 on all replicate pairs; cross R^2^ test) and the replicate sets were created for *sfpq*^*−/−*^*;Tg(mnx1:GFP)* and *sfpq*^*+/−; +/+*^*;Tg(mnx1:GFP)* by mean method for subsequent gene expression analyses. The scattered plot of the gene expression levels showed a high linear correlation (R^2^ = 0.98) between the two groups. Genes were considered differentially expressed when the level of expression change was at least two fold (upregulation or downregulation) in the homozygous *sfpq* embryos as compared to its WT siblings and the difference between the two groups was significant (p \< 0.01 moderated t test, in which the false discovery rate (FDR) was controlled by the Benjamini Hochberg correction method).

Ontology analysis conducted for the biological interpretation of the differentially expressed genes using ZFIN gene annotation file gave only few annotations as the microarray design is based on ZV7 release. Hence more recent gene annotations were downloaded from ZFIN (release 9, April 24^th^ 2013), and the probe sequences were aligned against the *D.rerio* genome from ENSEMBL release 71. The GO terms and hierarchy was downloaded from Gene Ontology (<http://www.geneontology.org>) on May 7^th^ 2013. All genes and functional annotations were imported in ArrayStar4 for further analysis, The GO terms with p \< 0.05 (after Benjamini Hochberg correction) and with percentage of genes per GO term above the percentage of the genes of its major/ first level GO classification is considered as enriched among the differentially expressed genes.

The number of variant transcripts per gene was obtained using the genome provided by ENSEMBL release 75 (Zfin v9, February 2014) ([@bib1]). The plots and computations were done using R version 3.1.0 (<http://www.R-project.org/>).

### Validation of microarray results {#sec4.5.2}

Validation of microarray results by qRT-PCR was performed on six randomly picked transcripts downregulated according to transcriptome analysis. The correlation of the gene expression data from microarray and qPCR was tested using Spearman's Rho test. Statistical comparison was performed using paired t test with Bonferroni correction for multiple comparisons.

### Splice variant analysis {#sec4.5.3}

Analysis of number of splice variants in whole transcriptome and DES transcriptome was performed using one-sided Wilcoxon-Mann-Whitney rank sum test with continuity correction based on the number of transcripts for each gene.

### Quantification of neuronal morphological parameters {#sec4.5.4}

Quantification of the α−SFPQ fluorescent signal in motor axons was done in double-blind on confocal stacks, for 5 pairs of motor axons per embryo using FiJi. Measurement was done in no less than 30 (max. 46) embryos per variant injected. Quantification of ventral motor axon lengths and branching complexity were made for 5 segments per embryo (always 5 somites anterior to the cloaca) on confocal stacks, using FIJI Single Neurite Tracer in no less than 28 (max. 41) embryos per variant injected. The variants significantly different from wild-type show same difference when comparing pairwise to the other variants (pairwise ANOVA, p \< 0.0001 and p \< 0.001 respectively).

Data and Software Availability {#sec4.6}
------------------------------

The accession number for the microarray datasets reported in this paper is ArrayExpress: [E-MTAB-5559](array-express:E-MTAB-5559){#intref0120}.
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